Can we afford to let sleeping dogs lie?

被引：17

作者：

Deininger, MWN ^{[1
]}

Holyoake, TL

机构：

[1] Oregon Hlth Sci Univ, Portland, OR 97201 USA

[2] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland

来源：

BLOOD | 2005年 / 105卷 / 05期

关键词：

D O I：

10.1182/blood-2004-12-4764

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In patients with chronic mvelogcnous leukemia (CML) mutations of the BCR-ABL kinase domain (KD) have been identified as the leading cause of acquired resistance to imatinib, while the mechanisms underlying the persistence of minimal residual disease (MRD) are unknown. In this issue of Blood, Chu and colleagues report several patients with KD mutations at the time of complete cytogenetic response (CCR), implicating mutations as a cause of disease persistence.

引用

页码：1840 / 1841

页数：2

共 7 条

[1] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].